High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer [0.03%]
高灵敏度ctDNA分析发现NGS遗漏的胰腺癌信号
Krishay Sridalla,Jasmine K Machhi,Dominic J Vitello et al.
Krishay Sridalla et al.
Purpose: Pancreatic ductal adenocarcinoma (PDAC) carries high mortality despite multimodal therapy, and improved biomarkers are needed to guide perioperative care. This study evaluated the prognostic significance of KRAS-...
Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG [0.03%]
儿童脑肿瘤联盟关于CD40激动剂sotigalimab治疗复发性中枢神经系统肿瘤患儿和新诊断的弥漫内生性桥脑胶质瘤年轻患者的1期研究
Holly B Lindsay,Catherine A Billups,Mehmet Kocak et al.
Holly B Lindsay et al.
Purpose: The PBTC-051 study is the first pediatric evaluation of a CD40 agonist and assessed the safety, pharmacokinetics, and preliminary efficacy of sotigalimab in children and young adults with recurrent or progressive...
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer [0.03%]
阿特朱单抗联合瓦利珠单抗（CDX-1127）与或不联合科美替尼治疗既往经治的不可切除胆道癌患者的II期随机研究
Thatcher Ross Heumann,Jiayun Lu,Hao Wang et al.
Thatcher Ross Heumann et al.
Purpose: The addition of MEK inhibition to PD-L1 blockade improves progression-free survival (PFS) in patients with advanced biliary tract cancer (BTC). While MEK inhibitors may increase tumor cell immunogenicity, they ca...
Camrelizumab, a patinib and radiotherapy in locally advanced, unresectable hepatocellular carcinoma: a phase 2 study [0.03%]
卡瑞利珠单抗、派安普利和放疗治疗局部晚期不可切除肝细胞癌的一项Ⅱ期研究
Hongzhi Wang,Kun Wang,Xuan Zheng et al.
Hongzhi Wang et al.
Purpose: Given the underexplored combination of immune checkpoint inhibitors, tyrosine kinase inhibitors (TKIs), and radiotherapy in locally advanced, unresectable hepatocellular carcinoma (HCC), this study aimed to evalu...
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer [0.03%]
胆道癌靶向治疗的分子和临床决定因素
Darren Cowzer,Henry Walch,Pranita Atri et al.
Darren Cowzer et al.
Purpose: Actionable genomic alterations occur in all anatomic subsets of biliary tract cancer (BTC); however, targeted therapies have not shown a survival advantage over cytotoxics, and resistance mechanisms require furth...
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial [0.03%]
基于人工智能的病理学分类器可预测恩杂鲁胺治疗转移性激素敏感前列腺癌敏感性的生物标志物分析：来自ENZAMET试验的资料
Sebastian Medina,Naoto Tokuyama,Vaishnavi Putcha et al.
Sebastian Medina et al.
Purpose: The ENZAMET trial established that enzalutamide added to androgen deprivation therapy (ADT) improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC), but treatment response is hetero...
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer [0.03%]
纳武单抗联合伊匹单抗一线治疗晚期非小细胞肺癌的早期疗效和安全性分析
Hossein Borghaei,David Balli,Luis G Paz-Ares et al.
Hossein Borghaei et al.
Purpose: To identify variables associated with early detriment on first-line dual immunotherapy from the phase III CheckMate 227 and CheckMate 9LA studies. ...
Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma [0.03%]
帕博利珠单抗联合同期放化疗治疗高危头颈部鳞癌患者的肿瘤和系统性免疫标志与疗效相关性研究
Lazar Vujanovic,Pedro Torres-Saavedra,Fei Tu et al.
Lazar Vujanovic et al.
Purpose: Patients with pathologically high-risk, HPV-negative HNSCC recur frequently despite adjuvant cisplatin-radiation therapy (CRT). As CRT can upregulate PD-1/L1 immune checkpoints, adding pembrolizumab may reverse t...
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck Cancer [0.03%]
帕博利珠单抗联合二甲双胍治疗转移性头颈部癌症患者的II期可行性研究
Olga Zamulko,Sam Nusbaum,Andrew Osterburg et al.
Olga Zamulko et al.
Background: Survival for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains low with
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study [0.03%]
一项针对转移性PDAC患者的II期、开放标签、随机对照研究，评估TGFβ抗体NIS793联合白蛋白结合型紫杉醇/吉西他滨对比安慰剂联合白蛋白结合型紫杉醇/吉西他滨的生物标志物分析
Marc Pelletier,Jie Yang,Mukta Joshi et al.
Marc Pelletier et al.
Background: Transforming Growth Factor Beta (TGFβ) plays a dual role in cancer, acting as a tumor suppressor early in disease but promoting progression and immune evasion when dysregulated. In pancreatic ductal adenocarc...